Skip to main content

Research Repository

Advanced Search

All Outputs (199)

Pre-hospital transdermal glyceryl trinitrate for transient ischaemic attack: data from the RIGHT-2 trial (2024)
Journal Article
Appleton, J. P., Dixon, M., Woodhouse, L. J., Anderson, C. S., Ankolekar, S., Cala, L., England, T. J., Godolphin, P. J., Krishnan, K., Mair, G., Muir, K. W., Potter, J., Price, C. I., Randall, M., Robinson, T. G., Roffe, C., Rothwell, P. M., Sandset, E. C., Saver, J. L., Siriwardena, A. N., …Bath, P. M. (in press). Pre-hospital transdermal glyceryl trinitrate for transient ischaemic attack: data from the RIGHT-2 trial. European Journal of Neurology,

Background: Ambulance trials assessing interventions in suspected stroke patients will recruit patients with currently active symptoms that will resolve into transient ischaemic attack (TIA). We assessed the safety and efficacy of glyceryl trinitrate... Read More about Pre-hospital transdermal glyceryl trinitrate for transient ischaemic attack: data from the RIGHT-2 trial.

Duration of Benefit and Risk of Dual Antiplatelet Therapy up to 72 Hours After Mild Ischemic Stroke and Transient Ischemic Attack (2024)
Journal Article
Guan, L., Han, S., Johnston, S. C., Bath, P. M., Amarenco, P., Yang, Y., Wang, T., Jing, J., Wang, C., Gao, Y., Chen, W., Yan, H., Wang, X., Wang, Y., Wang, Y., & Pan, Y. (2024). Duration of Benefit and Risk of Dual Antiplatelet Therapy up to 72 Hours After Mild Ischemic Stroke and Transient Ischemic Attack. Neurology, 103(7), https://doi.org/10.1212/wnl.0000000000209845

Background and Objectives
Clopidogrel-aspirin initiated within 72 hours of symptom onset is effective in patients with mild ischemic stroke or transient ischemic attack (TIA) in the Intensive Statin and Antiplatelet Therapy for Acute High-risk Intra... Read More about Duration of Benefit and Risk of Dual Antiplatelet Therapy up to 72 Hours After Mild Ischemic Stroke and Transient Ischemic Attack.

Comorbidities and Angiogenic Regulators Affect Endothelial Progenitor Cell Subtype Numbers in a Healthy Volunteer Control Group (2024)
Journal Article
Rakkar, K., Kadir, R. R. A., Othman, O. A., Sprigg, N., Bath, P. M., & Bayraktutan, U. (2024). Comorbidities and Angiogenic Regulators Affect Endothelial Progenitor Cell Subtype Numbers in a Healthy Volunteer Control Group. Stem Cell Reviews and Reports, https://doi.org/10.1007/s12015-024-10777-5

Endothelial progenitor cells (EPCs) are stem cells that can repair injured blood vessels through neovascularisation. This is achieved through secretion of growth factors and endothelial maturation. EPC numbers and function have been studied to determ... Read More about Comorbidities and Angiogenic Regulators Affect Endothelial Progenitor Cell Subtype Numbers in a Healthy Volunteer Control Group.

Metoclopramide to Prevent Pneumonia in Patients With Stroke and a Nasogastric Tube: Data From the PRECIOUS Trial (2024)
Journal Article
Sluis, W. M., de Jonge, J. C., Reinink, H., Woodhouse, L. J., Westendorp, W. F., Bath, P. M., van de Beek, D., van der Worp, H. B., & for the PRECIOUS Investigators. (2024). Metoclopramide to Prevent Pneumonia in Patients With Stroke and a Nasogastric Tube: Data From the PRECIOUS Trial. Stroke, https://doi.org/10.1161/strokeaha.124.047582

BACKGROUND:
A randomized trial suggested that treatment with metoclopramide reduces the risk of pneumonia in patients with acute stroke and a nasogastric tube. We assessed whether this finding could be replicated in a post hoc analysis of the random... Read More about Metoclopramide to Prevent Pneumonia in Patients With Stroke and a Nasogastric Tube: Data From the PRECIOUS Trial.

Outcome 1 year after ICH: Data from the Tranexamic acid for IntraCerebral Haemorrhage 2 (TICH-2) trial (2024)
Journal Article
Law, Z. K., Menon, C. S., Woodhouse, L. J., Appleton, J. P., Al-Shahi Salman, R., Robinson, T., Werring, D., Roffe, C., Dineen, R. A., Bath, P. M., & Sprigg, N. (2024). Outcome 1 year after ICH: Data from the Tranexamic acid for IntraCerebral Haemorrhage 2 (TICH-2) trial. European Stroke Journal, https://doi.org/10.1177/23969873241265939

Introduction:
The Tranexamic acid for IntraCerebral Haemorrhage-2 (TICH-2) trial reported no significant improvement in death and dependency at day 90 despite reductions in haematoma expansion, early neurological deterioration and early death. Howev... Read More about Outcome 1 year after ICH: Data from the Tranexamic acid for IntraCerebral Haemorrhage 2 (TICH-2) trial.

The Effect of Tranexamic Acid on Neurosurgical Intervention in Spontaneous Intracerebral Hematoma: Data From 121 Surgically Treated Participants From the Tranexamic Acid in IntraCerebral Hemorrhage-2 Randomized Controlled Trial (2024)
Journal Article
Hollingworth, M., Woodhouse, L. J., Law, Z. K., Ali, A., Krishnan, K., Dineen, R. A., Christensen, H., England, T. J., Roffe, C., Werring, D., Peters, N., Ciccone, A., Robinson, T., Członkowska, A., Bereczki, D., Egea-Guerrero, J. J., Ozturk, S., Bath, P. M., & Sprigg, N. (2024). The Effect of Tranexamic Acid on Neurosurgical Intervention in Spontaneous Intracerebral Hematoma: Data From 121 Surgically Treated Participants From the Tranexamic Acid in IntraCerebral Hemorrhage-2 Randomized Controlled Trial. Neurosurgery, 95(3), 605-616. https://doi.org/10.1227/neu.0000000000002961

BACKGROUND AND OBJECTIVES:
An important proportion of patients with spontaneous intracerebral hemorrhage (ICH) undergo neurosurgical intervention to reduce mass effect from large hematomas and control the complications of bleeding, including hemato... Read More about The Effect of Tranexamic Acid on Neurosurgical Intervention in Spontaneous Intracerebral Hematoma: Data From 121 Surgically Treated Participants From the Tranexamic Acid in IntraCerebral Hemorrhage-2 Randomized Controlled Trial.

Dysphagia after stroke: research advances in treatment interventions (2024)
Journal Article
Labeit, B., Michou, E., Trapl-Grundschober, M., Suntrup-Krueger, S., Muhle, P., Bath, P. M., & Dziewas, R. (2024). Dysphagia after stroke: research advances in treatment interventions. Lancet Neurology, 23(4), 418-428. https://doi.org/10.1016/s1474-4422%2824%2900053-x

After a stroke, most patients have dysphagia, which can lead to aspiration pneumonia, malnutrition, and adverse functional outcomes. Protective interventions aimed at reducing these complications remain the cornerstone of treatment. Dietary adjustmen... Read More about Dysphagia after stroke: research advances in treatment interventions.

Ninety‐Day Stroke Recurrence in Minor Stroke: Systematic Review and Meta‐Analysis of Trials and Observational Studies (2024)
Journal Article
Lim, A., Ma, H., Johnston, S. C., Singhal, S., Muthusamy, S., Wang, Y., …Phan, T. G. (2024). Ninety‐Day Stroke Recurrence in Minor Stroke: Systematic Review and Meta‐Analysis of Trials and Observational Studies. Journal of the American Heart Association, 13(9), Article e032471. https://doi.org/10.1161/jaha.123.032471

Background Risk of recurrence after minor ischemic stroke is usually reported with transient ischemic attack. No previous meta‐analysis has focused on minor ischemic stroke alone. The objective was to evaluate the pooled proportion of 90‐day stroke r... Read More about Ninety‐Day Stroke Recurrence in Minor Stroke: Systematic Review and Meta‐Analysis of Trials and Observational Studies.

Design of trials in lacunar stroke and cerebral small vessel disease: review and experience with the LACunar Intervention Trial 2 (LACI-2) (2024)
Journal Article
Blair, G., Appleton, J. P., Doubal, F. N., Mhlanga, I. I., Woodhouse, L. J., Bath, P. M., & Wardlaw, J. M. (2024). Design of trials in lacunar stroke and cerebral small vessel disease: review and experience with the LACunar Intervention Trial 2 (LACI-2). Stroke and Vascular Neurology, https://doi.org/10.1136/svn-2023-003022

Cerebral small vessel disease (cSVD) causes lacunar stroke (25% of ischaemic strokes), haemorrhage, dementia, physical frailty, or is 'covert', but has no specific treatment. Uncertainties about the design of clinical trials in cSVD, which patients t... Read More about Design of trials in lacunar stroke and cerebral small vessel disease: review and experience with the LACunar Intervention Trial 2 (LACI-2).

Allopurinol and blood pressure variability following ischemic stroke and transient ischemic attack: a secondary analysis of XILO-FIST (2024)
Journal Article
MacDonald, A. S., McConnachie, A., Dickie, D. A., Bath, P. M., Forbes, K., Quinn, T., …Dawson, J. (2024). Allopurinol and blood pressure variability following ischemic stroke and transient ischemic attack: a secondary analysis of XILO-FIST. Journal of Human Hypertension, 38, 307-313. https://doi.org/10.1038/s41371-024-00906-5

Blood Pressure Variability (BPV) is associated with cardiovascular risk and serum uric acid level. We investigated whether BPV was lowered by allopurinol and whether it was related to neuroimaging markers of cerebral small vessel disease (CSVD) and c... Read More about Allopurinol and blood pressure variability following ischemic stroke and transient ischemic attack: a secondary analysis of XILO-FIST.

Influence of Time to Achieve Target Systolic Blood Pressure on Outcome After Intracerebral Hemorrhage: The Blood Pressure in Acute Stroke Collaboration (2024)
Journal Article
Wang, X., Yang, J., Moullaali, T. J., Sandset, E. C., Woodhouse, L. J., Law, Z. K., Arima, H., Butcher, K. S., Delcourt, C., Mbbs, L. E., Gupta, S., Jiang, W., Koch, S., Potter, J., Qureshi, A. I., Robinson, T. G., Salman, R. A.-S., Saver, J. L., Sprigg, N., Wardlaw, J., …Chalmers, J. (2024). Influence of Time to Achieve Target Systolic Blood Pressure on Outcome After Intracerebral Hemorrhage: The Blood Pressure in Acute Stroke Collaboration. Stroke, 55(4), 849-855. https://doi.org/10.1161/STROKEAHA.123.044358

OBJECTIVE:
To investigate whether an earlier time to achieving and maintaining systolic blood pressure (SBP) at 120 to 140 mm Hg is associated with favorable outcomes in a cohort of patients with acute intracerebral hemorrhage.

METHODS:
We poole... Read More about Influence of Time to Achieve Target Systolic Blood Pressure on Outcome After Intracerebral Hemorrhage: The Blood Pressure in Acute Stroke Collaboration.

Influence of Time to Achieve Target Systolic Blood Pressure on Outcome after Intracerebral Hemorrhage: The Blood Pressure in Acute Stroke Collaboration (2024)
Presentation / Conference Contribution
Wang, X., Yang, J., Moullaali, T. J., Sandset, E. C., Woodhouse, L. J., Law, Z. K., Arima, H., Butcher, K. S., Delcourt, C., Edwards, L., Gupta, S., Jiang, W., Koch, S., Potter, J., Qureshi, A. I., Robinson, T. G., Al-Shahi Salman, R., Saver, J. L., Sprigg, N., Wardlaw, J., …Chalmers, J. (2023, May). Influence of Time to Achieve Target Systolic Blood Pressure on Outcome after Intracerebral Hemorrhage: The Blood Pressure in Acute Stroke Collaboration. Presented at European Stroke Organisation Conference, Munich

OBJECTIVE:
To investigate whether an earlier time to achieving and maintaining systolic blood pressure (SBP) at 120 to 140 mmHg is associated with favorable outcomes in a cohort of patients with acute intracerebral hemorrhage.

METHODS:
We poo... Read More about Influence of Time to Achieve Target Systolic Blood Pressure on Outcome after Intracerebral Hemorrhage: The Blood Pressure in Acute Stroke Collaboration.

Dual Antiplatelet Treatment up to 72 Hours after Ischemic Stroke (2023)
Journal Article
Gao, Y., Chen, W., Pan, Y., Jing, J., Wang, C., Johnston, S. C., …Wang, Y. (2023). Dual Antiplatelet Treatment up to 72 Hours after Ischemic Stroke. New England Journal of Medicine, 389(26), 2413-2424. https://doi.org/10.1056/nejmoa2309137

BACKGROUND: Dual antiplatelet treatment has been shown to lower the risk of recurrent stroke as compared with aspirin alone when treatment is initiated early (≤24 hours) after an acute mild stroke. The effect of clopidogrel plus aspirin as compared w... Read More about Dual Antiplatelet Treatment up to 72 Hours after Ischemic Stroke.

Analysis of endothelial progenitor cell subtypes as clinical biomarkers for elderly patients with ischaemic stroke (2023)
Journal Article
Kadir, R. R. A., Rakkar, K., Othman, O. A., Sprigg, N., Bath, P. M., & Bayraktutan, U. (2023). Analysis of endothelial progenitor cell subtypes as clinical biomarkers for elderly patients with ischaemic stroke. Scientific Reports, 13(1), Article 21843. https://doi.org/10.1038/s41598-023-48907-7

Endothelial progenitor cells (EPCs), expressing markers for stemness (CD34), immaturity (CD133) and endothelial maturity (KDR), may determine the extent of post-stroke vascular repair. Given the prevalence of stroke in elderly, this study explored wh... Read More about Analysis of endothelial progenitor cell subtypes as clinical biomarkers for elderly patients with ischaemic stroke.

Analysis of Endothelial Progenitor Cell Subtypes as Clinical Biomarkers for Elderly Patients with Ischaemic Stroke (2023)
Journal Article
ABDULKADIR, R., RAKKAR, K., OTHMAN, O., SPRIGG, N., BATH, P., & BAYRAKTUTAN, U. (2023). Analysis of Endothelial Progenitor Cell Subtypes as Clinical Biomarkers for Elderly Patients with Ischaemic Stroke. Scientific Reports, 13, Article 21843. https://doi.org/10.1038/s41598-023-48907-7

Endothelial progenitor cells (EPCs), expressing markers for stemness (CD34), immaturity (CD133) and endothelial maturity (KDR), may determine the extent of post-stroke vascular repair. Given the prevalence of stroke in elderly, this study explored wh... Read More about Analysis of Endothelial Progenitor Cell Subtypes as Clinical Biomarkers for Elderly Patients with Ischaemic Stroke.

Prevention of infections and fever to improve outcome in older patients with acute stroke (PRECIOUS): a randomised, open, phase III, multifactorial, clinical trial with blinded outcome assessment (2023)
Journal Article
de Jonge, J. C., Sluis, W. M., Reinink, H., Bath, P. M., Woodhouse, L. J., Zweedijk, B., …van der Worp, H. B. (2024). Prevention of infections and fever to improve outcome in older patients with acute stroke (PRECIOUS): a randomised, open, phase III, multifactorial, clinical trial with blinded outcome assessment. Lancet Regional Health – Europe, 36, Article 100782. https://doi.org/10.1016/j.lanepe.2023.100782

Background

Infections and fever after stroke are associated with poor functional outcome or death. We assessed whether prophylactic treatment with anti-emetic, antibiotic, or antipyretic medication would improve functional outcome in older patient... Read More about Prevention of infections and fever to improve outcome in older patients with acute stroke (PRECIOUS): a randomised, open, phase III, multifactorial, clinical trial with blinded outcome assessment.

Challenges and Experiences in Multicenter Prehospital Stroke Research: Narrative Data from the Rapid Intervention with Glyceryl Trinitrate in Hypertensive Stroke Trial-2 (RIGHT-2) (2023)
Journal Article
Dixon, M., Williams, J., Bath, P. M., Investigators, R.-2., & for the RIGHT-2 Investigators. (2024). Challenges and Experiences in Multicenter Prehospital Stroke Research: Narrative Data from the Rapid Intervention with Glyceryl Trinitrate in Hypertensive Stroke Trial-2 (RIGHT-2). Prehospital Emergency Care, 28(6), 832-840. https://doi.org/10.1080/10903127.2023.2287171

Background: Ambulance services are increasingly research active and the Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial-2 (RIGHT-2) is the largest United Kingdom (UK) ambulance-based randomized controlled trial in stroke. We... Read More about Challenges and Experiences in Multicenter Prehospital Stroke Research: Narrative Data from the Rapid Intervention with Glyceryl Trinitrate in Hypertensive Stroke Trial-2 (RIGHT-2).

Evaluating artificial intelligence software for delineating hemorrhage extent on CT brain imaging in stroke: AI delineation of ICH on CT. (2023)
Journal Article
Vacek, A., Mair, G., White, P., Bath, P. M., Muir, K. W., Al-Shahi Salman, R., …Wardlaw, J. M. (2024). Evaluating artificial intelligence software for delineating hemorrhage extent on CT brain imaging in stroke: AI delineation of ICH on CT. Journal of Stroke and Cerebrovascular Diseases, 33(1), Article 107512. https://doi.org/10.1016/j.jstrokecerebrovasdis.2023.107512

Background: : The extent and distribution of intracranial hemorrhage (ICH) directly affects clinical management. Artificial intelligence (AI) software can detect and may delineate ICH extent on brain CT. We evaluated e-ASPECTS software (Brainomix Ltd... Read More about Evaluating artificial intelligence software for delineating hemorrhage extent on CT brain imaging in stroke: AI delineation of ICH on CT..

Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage (2023)
Journal Article
Eilertsen, H., Menon, C. S., Law, Z. K., Chen, C., Bath, P. M., Steiner, T., …Al-Shahi Salman, R. (2023). Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage. Cochrane Database of Systematic Reviews, 2023(10), Article CD005951.pub5. https://doi.org/10.1002/14651858.CD005951.pub5

Background
Outcome after acute spontaneous (non‐traumatic) intracerebral haemorrhage (ICH) is influenced by haematoma volume. ICH expansion occurs in about 20% of people with acute ICH. Early haemostatic therapy might improve outcome by limiting ICH... Read More about Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage.